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INTRODUCTION
Ischaemic heart diseases and cerebrovascular diseases cause 
the highest number of deaths among the Polish population. 
Despite constant advances in treatment options, symptoms 
caused by obstructed arterioles and capillaries may be difficult 
to alleviate, especially because heavily calcified arteries may 
not qualify for interventional procedures [1]. 
On the other hand, formation of new blood vessels is 
a complex and integrated process. In angiogenesis, new mi-
crovessels are generated from preexisting vasculature by the 
proliferation and migration of endothelial cells [2]. This process 
is regulated by growth factors such as vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF), 
transforming growth factor (TGF), and angiopoietin-1.
Mesenchymal stem cells (MSCs) are a heterogeneous 
population of fibroblast-like multipotent cells that can differ-
entiate into various mesodermal lineages, such as adipocytes, 
chondrocytes, or cardiomyocytes. Many preclinical cardio-
vascular regenerative studies demonstrated that MSCs can 
alleviate cardiac insult and promote recovery in large animal 
models [3]. The most widely investigated stem cells for the 
treatment of heart failure or ischaemic heart disease are bone 
marrow-derived mesenchymal stromal cells.
Adipose-derived stromal cells (ADSCs), which are pro-
posed as a treatment option in this study, present similar cell 
characteristics to bone marrow stem cells. Nevertheless, they 
show a higher stem cell proliferation potential with greater 
yield of pluripotent stem cells [4]. 
On the other hand, based on animal experiments, 
neoangiogenesis and tissue perfusion may be stimulated by 
transmyocardial revascularisation because it induces a highly 
disorganised pattern of neovascularisation at the periphery 
in a nonspecific response similar to that observed in scar 
tissue [5].
Therefore, based on promising results from in vitro and 
animal studies, we delivered fresh ADSCs intramyocardially, 
with use of a medical laser, to patients with chronic ischae-
mic heart disease who did not qualify for standard methods 
of treatment (percutaneous coronary intervention, coronary 
artery bypass grafting). 
METHODS
A total of 15 patients with refractory angina (Canadian Car-
diovascular Society class II or greater), who were disqualified 
from direct myocardial revascularisation based on the deci-
sion of the Heart Team, were enrolled in the study. Other 
inclusion criteria comprised left ventricular ejection fraction 
(LVEF) greater than 20%, impaired endocardial movement 
and myocardial thickening at the anterior heart wall, and the 
absence of transmural scar at the anterior heart wall, based 
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on cardiac magnetic resonance examination (Table 1). The 
study was approved by the Bioethics Committee. All patients 
gave written consent to participate. 
During the procedure, fat tissue was collected from the 
abdominal area under general anaesthesia, similarly to stan-
dard liposuction procedure. The harvested tissue was purified 
using a Celution 800/CRS® System (Cytori Therapeutics, San 
Diego, CA, USA), to obtain a 5-mL suspension of ADSCs.
The average number of implanted stem cells was 
40 × 106. For cell purification we used dedicated medical 
equipment that enabled reliable and reproducible isolation 
of adipose-derived stromal cells from fat tissue [6]. ADSCs 
were implanted immediately to the same patient from whom 
they were obtained, simultaneously with myocardial laser 
revascularisation (Holmium:YAG laser) via left-sided mini-tho-
racotomy. During the procedure, five channels were created 
using low power (7 W), and around 1 mL of cell suspension 
was implanted for each channel with the use of a PHOENIX 
combined delivery system (CryoLife, Kennesaw, GA, USA).
RESULTS AND DISCUSSION
Overall, 15 patients aged from 55 to 74 years (mean age 
65 years) were enrolled, including 12 (80%) patients after 
myocardial injury. Mean LVEF was 36%, which was caused 
by myocyte destruction due to ischaemia. 
The proposed procedure is a feasible treatment option 
that may be performed safely in an experienced cardiac 
centre. The mean operative time was 179 min and adipose 
tissue was successfully harvested from all patients. We were 
able to follow the study protocol in all of the cases and there 
were no perioperative complications or significant changes in 
laboratory parameters from baseline levels observed. Moreo-
ver, the mean blood loss during the procedure was 70 mL 
and patients were discharged home on postoperative day 7. 
At the 30-day follow-up, we did not observe any major 
adverse cardiac or cerebrovascular events. During this period, 
patients did not require readmission due to cardiac causes.
Inclusion criteria ensured enrolment only of patients with 
confirmed eccentric left ventricular (LV) hypertrophy and LV 
systolic dysfunction due to ischaemia. Loss of active myocytes 
resulted in increased LV diastolic volume and consequently 
LV diastolic blood pressure, which was observed. Because 
LV pressure overload, along with neurohormonal changes, 
induces eccentric hypertrophy, all patients had hypokinesis 
or akinesis, impaired endocardial movement, and myocardial 
thickening at the anterior wall.
Nevertheless, the success of cell-based therapies depends 
on whether the engrafted cells differentiate into functional 
vascular cells and whether those cells can produce paracrine 
signals that encourage survival of the cells in the ischaemic 
environment [2].
Adipose-derived stromal cells are increasingly used in 
stem cell research. Freshly isolated ADSCs are known to be 
heterogeneous and contain haematopoietic cells (CD45+ 
and/or CD34+) and vascular endothelial cells (CD34+/ 
/CD31+) in addition to stem cells (CD44+ and CD105+). 
Table 1. Baseline characteristics and perioperative results
Baseline characteristics Analysed population 
(n = 15)
Chronic ischaemic heart disease 15 (100%)
Age [years] 65 (55–74)
Body mass index [kg/m2] 29.8 (24–42)
BSA women [m2] 1.7 (1.5–1.9)
BSA men [m2] 1.93 (1.7–2.2)
Prior MI 12 (8%)
Hypertension 14 (93%)
Diabetes 5 (33%)
Prior PCI 5 (33%)
Prior CABG 3 (20%)
Hypercholesterolaemia 13 (87%)
Peripheral artery disease 5 (33%)
CCS class II 5 (33%)
CCS class III or IV 10 (67%)
Left anterior descending artery:
Chronic total occlusion 9 (60%)
Significant stenosis (75–99% stenosis) 6 (40%)
CMR baseline results:
LVEDV/BSA [mL/m2] 135 (96.1–213)
LVESV/BSA [mL/m2] 91 (45.8–169)
LVSV [mL] 80.5 ± 8.1
LVM/BSA women [g/m2] 86
LVM/BSA men [g/m2] 104
LVEF [%] 36 (20–52)
Periprocedural outcomes:
Mean procedure duration [min] 179 
Amount of harvested fat tissue [mL] 220 (120–360)
Cardiovascular complications  
(MI, death, haemodynamic instability)
0 (0%)
Malignant arrhythmia 0 (0%)
Harvest side complications  
(bleeding, infections)
0 (0%)
30-days outcomes:
Major adverse cardiac event 0 (0%)
Readmission due to cardiac causes 0 (0%) 
Data shown as mean ± standard deviation or as median (interquartile 
range), or number (percentage). BSA — body surface area; CABG — 
coronary artery bypass grafting; CMR — cardiac magnetic resonance; 
CCS — Canadian Cardiovascular Society; LVM — left ventricular mass; 
LVEDV — left ventricular end-diastolic volume; LVEF — left ventricular 
ejection fraction; LVESV — left ventricular end-systolic volume; LVSV —  
left ventricular systolic volume; MI — myocardial infarction; PCI — 
percutaneous coronary intervention
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Schenke-Layland et al. [7] showed that the ADSC-treated 
group presented lower LV end-diastolic dimension, and 
significantly improved LVEF and cardiac output [7]. Rehman 
et al. [8] examined the production of paracrine factors by 
human ADSCs and showed that ADSCs produce VEGF, bFGF, 
and TGF-b. The paracrine effect of transplanted stem cells has 
been emphasised recently. 
The aim of ADSC implantation in patients with chronic is-
chaemic heart disease was to initiate angiogenesis in ischaemic 
myocardium, which would slow down the process of adverse 
LV remodelling and heart failure development.
In particular, the paracrine effect from transplanted 
ADSCs may play a major role in this process. Administered 
mesenchymal stromal cells were fresh and co-administered 
with stromal vascular fraction, which may also be involved 
in stem cell activation. 
Left sided mini-thoracotomy is a safe and proven method 
to gain access to the anterior heart wall and allows ADSC 
implantation at the scheduled area of the heart muscle. There 
were no difficulties with the identification of the administra-
tion site or with the process of implantation.
To intensify the process of mesenchymal stromal cell 
activation, we used a medical laser. Around the channel 
formed by the laser, a special “border zone” was created. 
The cytokines released in this area probably serve as a “hom-
ing” signal for circulating stem cells, particularly endothelial 
progenitor cells.
Animal experiments suggest that transmyocardial revas-
cularisation induces a highly disorganised pattern of neovas-
cularisation at the periphery in a nonspecific response similar 
to that observed in scar tissue. Atluri et al. [5] also revealed 
significant increases in angiogenesis and perfusion. 
An important part of any study using innovative therapeu-
tic methods is to ensure patient safety. It should be emphasised 
that during the procedures there were no complications and 
patients were discharged home in good general condition.
During the 30-day follow-up, no patient required hos-
pitalisation for heart disease. The patients did not report 
exacerbation of symptoms of angina pectoris. The final ef-
fect of the applied innovative therapy will be evaluated at 
12 months post-surgery. 
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